Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin.

Liu F, Levin MD, Petrenko NB, Lu MM, Wang T, Yuan LJ, Stout AL, Epstein JA, Patel VV.

J Mol Cell Cardiol. 2008 Dec;45(6):715-23. doi: 10.1016/j.yjmcc.2008.08.015. Epub 2008 Sep 16.

2.

Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy.

Van Wagoner DR, Nattel S.

J Mol Cell Cardiol. 2008 Dec;45(6):707-8. doi: 10.1016/j.yjmcc.2008.09.001. Epub 2008 Sep 10. No abstract available.

PMID:
18817781
3.

HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.

Ooi JY, Tuano NK, Rafehi H, Gao XM, Ziemann M, Du XJ, El-Osta A.

Epigenetics. 2015;10(5):418-30. doi: 10.1080/15592294.2015.1024406. Epub 2015 May 5.

4.

Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding.

Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z, Ahn Y, Jeong MH, Bang YJ, Kim N, Kim JK, Kim KK, Epstein JA, Kook H.

Circulation. 2006 Jan 3;113(1):51-9. Epub 2005 Dec 27.

5.

Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation.

Seki M, LaCanna R, Powers JC, Vrakas C, Liu F, Berretta R, Chacko G, Holten J, Jadiya P, Wang T, Arkles JS, Copper JM, Houser SR, Huang J, Patel VV, Recchia FA.

J Pharmacol Exp Ther. 2016 Sep;358(3):441-9. doi: 10.1124/jpet.116.234591. Epub 2016 Jun 27.

PMID:
27353074
6.

CYP2J2 overexpression protects against arrhythmia susceptibility in cardiac hypertrophy.

Westphal C, Spallek B, Konkel A, Marko L, Qadri F, DeGraff LM, Schubert C, Bradbury JA, Regitz-Zagrosek V, Falck JR, Zeldin DC, Müller DN, Schunck WH, Fischer R.

PLoS One. 2013 Aug 30;8(8):e73490. doi: 10.1371/journal.pone.0073490. eCollection 2013.

7.
8.

HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling.

Demos-Davies KM, Ferguson BS, Cavasin MA, Mahaffey JH, Williams SM, Spiltoir JI, Schuetze KB, Horn TR, Chen B, Ferrara C, Scellini B, Piroddi N, Tesi C, Poggesi C, Jeong MY, McKinsey TA.

Am J Physiol Heart Circ Physiol. 2014 Jul 15;307(2):H252-8. doi: 10.1152/ajpheart.00149.2014. Epub 2014 May 23.

9.

An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy.

Zhai P, Galeotti J, Liu J, Holle E, Yu X, Wagner T, Sadoshima J.

Circ Res. 2006 Sep 1;99(5):528-36. Epub 2006 Aug 10.

10.

Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis.

Zhang L, Qin X, Zhao Y, Fast L, Zhuang S, Liu P, Cheng G, Zhao TC.

J Pharmacol Exp Ther. 2012 Apr;341(1):285-93. doi: 10.1124/jpet.111.189910. Epub 2012 Jan 23.

11.

Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.

Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson EN, Hill JA.

Circulation. 2006 Jun 6;113(22):2579-88. Epub 2006 May 30.

12.

Inhibition of histone deacetylase-induced myocardial repair is mediated by c-kit in infarcted hearts.

Zhang L, Chen B, Zhao Y, Dubielecka PM, Wei L, Qin GJ, Chin YE, Wang Y, Zhao TC.

J Biol Chem. 2012 Nov 16;287(47):39338-48. doi: 10.1074/jbc.M112.379115. Epub 2012 Sep 28.

13.

Pan-histone deacetylase inhibitors regulate signaling pathways involved in proliferative and pro-inflammatory mechanisms in H9c2 cells.

Majumdar G, Adris P, Bhargava N, Chen H, Raghow R.

BMC Genomics. 2012 Dec 18;13:709. doi: 10.1186/1471-2164-13-709.

14.
15.

Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition.

Zhang LX, Zhao Y, Cheng G, Guo TL, Chin YE, Liu PY, Zhao TC.

Am J Physiol Heart Circ Physiol. 2010 Jun;298(6):H2154-63. doi: 10.1152/ajpheart.01015.2009. Epub 2010 Apr 9.

16.

Prevention of Pulmonary Fibrosis via Trichostatin A (TSA) in Bleomycin Induced Rats.

Ye Q, Li Y, Jiang H, Xiong J, Xu J, Qin H, Liu B.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):219-26.

PMID:
25363222
17.

Changes in cardiac Nav1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors.

Xu Q, Patel D, Zhang X, Veenstra RD.

Am J Physiol Heart Circ Physiol. 2016 Nov 1;311(5):H1139-H1149. doi: 10.1152/ajpheart.00156.2016. Epub 2016 Sep 16.

PMID:
27638876
18.

Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop.

Kook H, Lepore JJ, Gitler AD, Lu MM, Wing-Man Yung W, Mackay J, Zhou R, Ferrari V, Gruber P, Epstein JA.

J Clin Invest. 2003 Sep;112(6):863-71.

19.

Elevated dietary sodium intake exacerbates myocardial hypertrophy associated with cardiac-specific overproduction of angiotensin II.

Porrello ER, Huggins CE, Curl CI, Domenighetti AA, Pedrazzini T, Delbridge LM, Morgan TO.

J Renin Angiotensin Aldosterone Syst. 2004 Dec;5(4):169-75.

PMID:
15806712
20.

Histone deacetylase as a new target for cancer chemotherapy.

Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S.

Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S20-6. Review.

PMID:
11587361

Supplemental Content

Support Center